Selected as a participating company in the Japanese Cancer Research Project "SCRUM-Japan MONSTER Screen3" at the National Cancer Center Hospital East (NCCH).
2024
202410
Registered as a mail-order business.
202409
Successfully completed the KGMP (Korea Good Manufacturing Practice) certification audit.
202408
Acquired GenomeCare.Registered as a Health Functional Food Sales Business.
202404
Established a branch office for medical device sales.
202401
Established Cytogen Japan.
2023
202305
Completed re-registration as a foreign manufacturer and finalized three medical device manufacturing and sales notifications with the PMDA (Japan).
2022
202212
Acquired ExperTox.
202204
Established Cytogen Health.
202203
Renewed ISO 13485:2016 certification.
2021
202103
Designated as a GCLP (Good Clinical Laboratory Practice) institution for clinical trial sample analysis.
2020
202006
Selected for the Core Technology Development Project by the Ministry of Trade, Industry and Energy (MOTIE).
202002
Signed an MOU with UMUST R&D for the preclinical drug evaluation of pancreatic cancer.
2019
201910
Signed a joint antibody development agreement with Thermo Fisher Scientific.
201906
Signed a contract for a PDX CTC analysis project (Client W).
201901
Obtained MFDS (Ministry of Food and Drug Safety) approval for Cell Isolator Kit (CIKW10).
